{"favorite_id": 2153, "calc_type": "calculator", "dosing": false, "full_title_en": "Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)", "short_title_en": "MSKCC/Motzer Criteria for RCC", "medium_description_en": "Predicts survival based on clinical and laboratory data in metastatic RCC patients.", "short_description_en": "Predicts survival in RCC patients.", "before_use": "", "instructions_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Use baseline factors at the start date of the current line of systemic therapy, except for the &ldquo;time of diagnosis to systemic therapy&rdquo; criterion, which is always relative to first-line therapy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Always <calculator id=\"31\">correct calcium concentration</calculator> for low albumin before scoring.</p>\n</li>\n</ul>", "purpose_en": ["Prognosis"], "disease_en": ["Renal Cell Carcinoma", "Chemotherapy"], "specialty_en": ["Hematology and Oncology", "Nephrology", "Urology"], "chief_complaint_en": ["Hematuria"], "system_en": ["Oncologic", "Renal", "Urinary"], "search_abbreviation_en": ["RCC", "MSKCC", "Sloan-Kettering", "Sloan Kettering", "Motzer", "renal cancer", "kidney cancer", "karnofsky", "nephrectomy", "survival"], "slug": "memorial-sloan-kettering-cancer-center-mskcc-motzer-score-metastatic-renal-cell-carcinoma-rcc", "seo": {"meta_description_en": "The MSKCC/Motzer Criteria for RCC predicts survival based on clinical and laboratory data in metastatic RCC patients.", "keywords_en": "mskcc, mskcc score, rcc score, motzer score, mskcc motzer score, rcc prognosis, sloan kettering cancer score, sloan kettering cancer prognosis, sloan kettering rcc score, renal cell carcinoma score"}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-47933021-7fff-bc4d-ea35-a269302237f9\">Patients with metastatic RCC undergoing systemic therapy and being considered for clinical trial enrollment, and in clinical practice for the estimation of prognosis.</p>", "pearls_pitfalls_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Initially created in the pre-targeted therapy era of RCC, but has since been validated in patients receiving targeted therapy (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23312463\" target=\"_blank\">Heng 2013</a>).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple other models have since been established based on the MSKCC/Motzer score, including:</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><calculator id=\"3007\">Mekhail Extension of the Motzer Score</calculator></p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><calculator id=\"3008\">IMDC (International Metastatic RCC Database Consortium) Risk Model</calculator></p>\n</li>\n</ul>\n</ul>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">May assist in estimating prognosis of patients with metastatic RCC, but is not currently used for making decisions about treatment (use IMDC Risk Model instead).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Easy to use and uses readily available clinical and laboratory variables.</p>\n</li>\n</ul>", "why_use_en": "<p>Assists clinicians in discussions about prognosis for patients with metastatic RCC and can be used as a stratification factor in clinical trials.</p>"}, "next_steps": {"advice_en": "", "management_en": "<p><span id=\"docs-internal-guid-d74042ae-7fff-80ad-7146-31ccf189df56\">The score is currently not used for treatment decision-making. The <calculator id=\"3008\">IMDC Risk Model</calculator>, which was originally based on the MSKCC/Motzer score, is currently used in treatment decision-making for metastatic RCC (<a href=\"https://www.nccn.org/professionals/physician_gls/\" target=\"_blank\">NCCN Guidelines 2019)</a>.</p>", "critical_actions_en": "<p><span id=\"docs-internal-guid-4c639a32-7fff-bf6d-b966-b86b331da63a\">Can only be applied to patients with metastatic RCC that receive systemic therapy.</p>"}, "about": {"formula_en": "<p>Addition of selected points, as above.</p>", "more_info_en": "<p><span id=\"docs-internal-guid-f039d8ab-7fff-710f-1cef-72f9a9264e61\">Interpretation:</p>\n<div class=\"table-responsive\">\n<table class=\"table table-bordered table-hover\">\n<tbody>\n<tr>\n<th>Score</th>\n<th style=\"text-align: left;\">Risk</th>\n<th style=\"text-align: left;\">\n<p>Median survival</p>\n</th>\n</tr>\n<tr>\n<td>0</td>\n<td>\n<p>Good</p>\n</td>\n<td>20 months</td>\n</tr>\n<tr>\n<td>1 - 2</td>\n<td>\n<p>Intermediate</p>\n</td>\n<td>10 months</td>\n</tr>\n<tr>\n<td>&ge;3</td>\n<td>\n<p>High</p>\n</td>\n<td>4 months</td>\n</tr>\n</tbody>\n</table>\n</div>", "evidence_based_medicine_en": "<p dir=\"ltr\">The MSKCC/Motzer score in its current form was initially derived from a 2002 retrospective study reviewing data from 463 patients, who had been enrolled in six clinical trials, with metastatic RCC treated with first-line interferon-alpha. The five variables that make up the model were found to be significantly related to overall survival on multivariable analysis (<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11773181\" target=\"_blank\">Motzer 2002</a>).</p>\n<p dir=\"ltr\">Multiple external validation studies were subsequently conducted on modified versions of the model either in the first-line setting (<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15681528\" target=\"_blank\">Mekhail 2005</a>) or in the second-line setting in the pre-targeted therapy era (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646307/\" target=\"_blank\">Motzer 2004</a>). Furthermore, <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23312463\" target=\"_blank\">Heng et al (2013)</a> validated the original MSKCC Model and compared it to other similar models in the targeted therapy era. However, this study suggested that the <calculator id=\"3008\">IMDC Risk Model</calculator> has superior prognostic power over the MSKCC model. Although the two models were found to be highly concordant, the IMDC model showed better fit and reclassification accuracy.</p>\n<p dir=\"ltr\">The MSKCC risk group is still among the most frequently used risk models for metastatic RCC, and is often reported along with the IMDC model in clinical trials.</p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/10561319", "text": "Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-40."}], "Other References": [], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/11773181", "text": "Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002 Jan 1;20(1):289-96."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/14752067", "text": "Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454-63."}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed/15681528", "text": "Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005 Feb 1;23(4):832-41."}, {"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646307/", "text": "Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-90."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/23312463", "text": "Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-8."}], "Clinical Practice Guidelines": [{"href": "https://www.nccn.org/professionals/physician_gls/", "text": "NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. V 2.2019."}], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "<p>Ziad Bakouny, MD, MSc, is a postdoctoral genitourinary oncology research fellow at the Dana-Farber Cancer Institute/Harvard Cancer Center. Dr. Bakouny received his medical degree from the University of Saint Joseph in Beirut, Lebanon, during which time he concurrently obtained a master\u2019s in biomechanics and medical imaging. He has published more than 30 peer-reviewed papers, presented 70 abstracts at international scientific conferences, and received various awards for his research, including a Conquer Cancer Foundation merit award at the American Society of Clinical Oncology and Society for Immunotherapy of Cancer\u2019s clinical immuno-oncology symposium. His areas of interest include genitourinary oncology, biomarker research, and bioinformatics.</p>", "firstName": "Ziad", "img": "https://cdn-web-img.mdcalc.com/people/ziad-bakouny.jpg", "lastName": "Bakouny", "name": "Ziad Bakouny, MD, MSc", "target": "ziad-bakouny", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": [{"name": "Toni Choueiri, MD"}]}, "creator": [{"name": "Dr. Robert J. Motzer", "creator_info": {"about_en": "<p><p>Robert J. Motzer, MD, is a medical oncologist at Memorial Sloan Kettering Cancer Center. He received the Career Development Award from the National Institutes of Health and the <a href='http://www.kidneycancer.org/about-us/research/' target='_blank'>Schonfeld Award from the Kidney Cancer Association</a>. Dr. Motzer\u2019s research focuses on renal cell carcinoma, germ-cell tumors, and bone marrow and blood cell transplantation.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-robert-j-motzer.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Motzer%20RJ%5Bauth%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [{"link": "https://www.mdcalc.com/rcc-renal-cell-carcinoma-practice-pearls", "text": "Practice Pearls: Renal Cell Carcinoma"}], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Time from diagnosis to systemic treatment <1 year", "name": "neph", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "tips_en": "Measured ~1 month after stopping anticoagulation", "optional": false}, {"type": "toggle", "label_en": "Hemoglobin < Lower Limit of Normal", "name": "hb", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "tips_en": "<ul><li>Men (Normal): 13.5-17.5 g/dL</li><li>Women (Normal): 12.0-15.5 g/dL</li></ul>", "optional": false}, {"type": "toggle", "label_en": "Calcium >10mg/dL (>2.5 mmol/L)", "name": "ca", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "LDH > 1.5x Upper Limit of Normal", "name": "ldh", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "tips_en": "Normal: 140 U/L", "optional": false}, {"type": "toggle", "label_en": "Performance status <80% (Karnofsky)", "name": "karnofsky", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}], "md5": "5b29e62f9a2de8a3c50d1df903e3af02", "cmeVersion": "2153.1", "related_calcs": [{"calcId": 3012, "short_title_en": "Fuhrman Nuclear Grade", "slug": "fuhrman-nuclear-grade-clear-cell-renal-carcinoma"}, {"calcId": 3908, "short_title_en": "RENAL Nephrometry Score", "slug": "renal-nephrometry-score"}, {"calcId": 3007, "short_title_en": "Mekhail Extension", "slug": "mekhail-extension-of-the-motzer-score"}]}